HHBT logo

HH Biotechnology Holdings Company (HHBT) Hisse Analizi

Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

HH Biotechnology Holdings Company (HHBT), Real Estate sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Hisse senedi, 9 kantitatif KPI'ya dayalı olarak orta dereceli bir derecelendirme olan 50/100 puan alıyor.

Son analiz: 17 Mar 2026
50/100 AI Puanı

HH Biotechnology Holdings Company (HHBT) Gayrimenkul Portföyü ve Stratejisi

CEOSheng Jiang
Çalışanlar121
MerkezShenyang, CN
Halka Arz Yılı2005

HH Biotechnology Holdings Company, operating in the real estate services sector, cultivates and supplies macadamia nuts for diverse applications. With a 31.0% profit margin, the company focuses on health and green industries, distinguishing itself through its agricultural focus within the real estate landscape.

Veri Kaynağı | Finansal Veriler Kantitatif Analiz NASDAQ Analiz: 17 Mar 2026

Yatırım Tezi

HH Biotechnology Holdings Company presents a unique investment proposition within the real estate services sector due to its focus on macadamia nut cultivation. The company's 31.0% profit margin indicates operational efficiency, while its 29.5% gross margin reflects the profitability of its core business. Key value drivers include the increasing demand for macadamia nuts in various industries and the company's established presence in the Chinese market. Potential catalysts include expansion into new geographic regions and diversification of product offerings. However, investors may want to evaluate the high beta of 4.45, indicating significant volatility, and the absence of dividends, which may deter income-seeking investors. The company's success hinges on its ability to scale production, manage costs, and navigate the competitive landscape.

FMP finansallarına ve nicel analizine dayanmaktadır

Temel Önemli Noktalar

  • Profit Margin of 31.0% indicates strong operational efficiency.
  • Gross Margin of 29.5% reflects the profitability of macadamia nut cultivation.
  • Beta of 4.45 suggests high volatility compared to the market.
  • Focus on health and green industries aligns with growing consumer trends.
  • Headquartered in Shenyang, China, providing access to a large and growing market.

Rakipler & Benzerleri

Güçlü Yönler

  • Specialization in macadamia nut cultivation.
  • Established presence in the Chinese market.
  • Focus on health and green industries.
  • Profit Margin of 31.0%.

Zayıflıklar

  • High beta of 4.45.
  • Lack of dividend payments.
  • Limited geographic diversification.
  • Small number of employees (121).

Katalizörler

  • Upcoming: Potential expansion into international markets within 2-3 years.
  • Upcoming: Diversification of product offerings within 1-2 years.
  • Ongoing: Strategic partnerships with food and cosmetic companies within 1 year.
  • Ongoing: Investment in research and development to improve macadamia nut yields.
  • Ongoing: Implementation of sustainable farming practices to reduce environmental impact.

Riskler

  • Potential: Competition from larger agricultural companies.
  • Potential: Fluctuations in macadamia nut prices.
  • Potential: Changes in consumer preferences.
  • Potential: Economic downturns.
  • Ongoing: Limited financial disclosure due to OTC Other listing.

Büyüme Fırsatları

  • Expansion into international markets: HH Biotechnology Holdings Company can explore opportunities to export macadamia nuts to countries with high demand for healthy snacks and plant-based ingredients. The global macadamia market is projected to reach $2.15 billion by 2028, presenting a significant growth opportunity. Timeline: 2-3 years.
  • Diversification of product offerings: The company can expand its product line to include macadamia nut-based products such as macadamia oil, macadamia butter, and macadamia flour. This diversification can cater to a wider range of consumer preferences and increase revenue streams. The market for plant-based products is growing rapidly, with a projected value of $74.2 billion by 2027. Timeline: 1-2 years.
  • Strategic partnerships with food and cosmetic companies: HH Biotechnology Holdings Company can collaborate with food and cosmetic manufacturers to supply macadamia nuts for their products. These partnerships can provide a stable demand for the company's macadamia nuts and increase its market reach. The food and cosmetic industries are increasingly seeking natural and sustainable ingredients, creating opportunities for macadamia nut suppliers. Timeline: 1 year.
  • Investment in research and development: The company can invest in research and development to improve macadamia nut yields, develop new macadamia nut varieties, and enhance the quality of its products. This can provide a competitive advantage and increase the value of its macadamia nuts. The agricultural technology market is growing rapidly, with a projected value of $30.9 billion by 2025. Timeline: Ongoing.
  • Implementation of sustainable farming practices: HH Biotechnology Holdings Company can adopt sustainable farming practices to reduce its environmental impact and appeal to environmentally conscious consumers. This can enhance the company's reputation and attract customers who prioritize sustainability. The market for sustainable products is growing rapidly, with a projected value of $150 billion by 2021. Timeline: Ongoing.

Fırsatlar

  • Expansion into international markets.
  • Diversification of product offerings.
  • Strategic partnerships with food and cosmetic companies.
  • Investment in research and development.

Tehditler

  • Competition from larger agricultural companies.
  • Fluctuations in macadamia nut prices.
  • Changes in consumer preferences.
  • Economic downturns.

Rekabet Avantajları

  • Specialization in macadamia nut cultivation.
  • Established presence in the Chinese market.
  • Focus on health and green industries.
  • Potential for sustainable farming practices.

HHBT Hakkında

HH Biotechnology Holdings Company, originally incorporated in 1987 as Great China International Holdings, Inc., transitioned to its current name in August 2016 to reflect its focus on health and green industries. Headquartered in Shenyang, People's Republic of China, the company specializes in the cultivation and supply of macadamia nuts. These nuts are utilized across various sectors, including food, cooking oils, healthy products, toiletries, and cosmetics. The company's operations are centered around providing high-quality macadamia nuts to meet the growing demand for natural and healthy ingredients. With 121 employees, HH Biotechnology Holdings Company aims to capitalize on the increasing consumer interest in health-conscious products and sustainable practices. The company's strategic shift towards macadamia nut production positions it within the broader agricultural sector, aligning with the rising global demand for plant-based ingredients and natural resources.

Ne Yaparlar

  • Cultivates macadamia nuts.
  • Supplies macadamia nuts to food manufacturers.
  • Provides macadamia nuts for cooking oil production.
  • Offers macadamia nuts for healthy product formulations.
  • Supplies macadamia nuts for toiletries and cosmetics.
  • Focuses on health and green industries.

İş Modeli

  • Cultivation and harvesting of macadamia nuts.
  • Sale of macadamia nuts to various industries.
  • Revenue generation through product sales.
  • Focus on sustainable and environmentally friendly practices.

Sektör Bağlamı

HH Biotechnology Holdings Company operates within the real estate services sector, with a specific focus on agricultural activities related to macadamia nut production. The global macadamia market is experiencing growth driven by increasing demand for healthy snacks, plant-based ingredients, and natural cosmetics. The competitive landscape includes agricultural companies, food producers, and cosmetic manufacturers. HH Biotechnology Holdings Company differentiates itself through its specialization in macadamia nuts and its presence in the Chinese market. The company's success depends on its ability to compete with larger agricultural players and capitalize on the growing demand for macadamia nuts in various industries.

Kilit Müşteriler

  • Food manufacturers.
  • Cooking oil producers.
  • Healthy product companies.
  • Toiletries and cosmetics manufacturers.
AI Güveni: 69% Güncellendi: 17 Mar 2026

Finansallar

Grafik & Bilgi

HH Biotechnology Holdings Company (HHBT) hisse senedi fiyatı: Price data unavailable

Son Haberler

Analist Konsensüsü

Fikir Birliği Derecelendirmesi

HHBT için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.

Fiyat Hedefleri

HHBT için Wall Street fiyat hedefi analizi.

MoonshotScore

50/100

Bu puan ne anlama geliyor?

MoonshotScore, HHBT'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.

Yönetim: Sheng Jiang

CEO

Sheng Jiang is the CEO of HH Biotechnology Holdings Company, overseeing the company's operations in the health and green industries. His background includes experience in managing teams and driving strategic initiatives. He is responsible for the company's overall performance and growth. With a focus on sustainable practices and innovation, Sheng Jiang aims to position HH Biotechnology Holdings Company as a leader in the macadamia nut industry.

Sicil: Under Sheng Jiang's leadership, HH Biotechnology Holdings Company has focused on expanding its macadamia nut cultivation and supply operations. Key milestones include increasing production capacity and establishing partnerships with food and cosmetic companies. His strategic decisions have contributed to the company's growth and profitability. He manages 121 employees.

HHBT OTC Piyasa Bilgileri

The OTC Other tier represents the lowest tier of the OTC market, indicating that HH Biotechnology Holdings Company may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks involves higher risks due to the lack of regulatory oversight and transparency.

  • OTC Katmanı: OTC Other
  • Açıklama Durumu: Unknown
Likidite: Liquidity in OTC Other stocks like HHBT is typically very low, with wide bid-ask spreads and limited trading volume. This can make it difficult for investors to buy or sell shares without significantly impacting the price. The lack of liquidity increases the risk of price volatility and makes it challenging to exit positions quickly. Investors should be prepared for potential delays and higher transaction costs when trading HHBT.
OTC Risk Faktörleri:
  • Limited financial disclosure.
  • Low liquidity and high price volatility.
  • Lack of regulatory oversight.
  • Potential for fraud and manipulation.
  • Difficulty in obtaining reliable information.
Durum Tespiti Kontrol Listesi:
  • Verify the company's registration and legal status.
  • Review available financial statements and disclosures.
  • Assess the company's business model and competitive landscape.
  • Evaluate the management team and their track record.
  • Check for any regulatory actions or legal issues.
  • Monitor trading volume and price activity.
  • Consult with a financial advisor.
Meşruiyet Sinyalleri:
  • Company has been in business since 1987.
  • Focus on a specific niche market (macadamia nuts).
  • Presence of a CEO (Sheng Jiang).
  • 121 employees suggest some scale of operations.
  • Profit margin of 31.0% indicates some financial viability.

HHBT Real Estate Hisse Senedi SSS

HHBT için değerlendirilmesi gereken temel faktörler nelerdir?

HH Biotechnology Holdings Company (HHBT) şu anda yapay zeka skoru 50/100, orta puanı gösteriyor. Temel güçlü yan: Specialization in macadamia nut cultivation.. İzlenmesi gereken birincil risk: Potential: Competition from larger agricultural companies.. Bu bir finansal tavsiye değildir.

HHBT MoonshotScore'u nedir?

HHBT şu anda MoonshotScore'da 50/100 (Derece C) alıyor, bu da orta derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.

HHBT verileri ne sıklıkla güncellenir?

HHBT fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.

Analistler HHBT hakkında ne diyor?

HHBT için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.

HHBT'a yatırım yapmanın riskleri nelerdir?

HHBT için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from larger agricultural companies.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.

HHBT'ın P/E oranı nedir?

HHBT için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için HHBT'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.

HHBT aşırı değerli mi, yoksa düşük değerli mi?

HH Biotechnology Holdings Company (HHBT)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.

HHBT'ın temettü verimi nedir?

HH Biotechnology Holdings Company (HHBT) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.

Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.

Resmi Kaynaklar

Analiz güncellendi AI Puanı günlük olarak yenilenir
Veri Kaynakları ve Metodoloji
Piyasa verileri Financial Modeling Prep ve Yahoo Finance tarafından sağlanmaktadır. AI analizi Stock Expert AI tescilli algoritmaları ile yapılmaktadır. Teknik göstergeler endüstri standardı hesaplamalarla üretilmektedir. Son güncelleme: .

Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.

Analiz Notları
  • AI analysis pending for HHBT.
  • Limited information available on OTC Other stocks.
Veri Kaynakları

Popüler Hisseler